Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03516695 · ClinicalTrials.gov registry record
RadioEmbolization for the ADvancement of Y90 Glass Microspheres Registry
A clinical trial, sponsored by Boston Scientific Corporation.
- Terminated
- Registry status
- 95
- Enrollment target
NCT03516695: Clinical Trial study, sponsored by Boston Scientific Corporation.
NCT03516695 is a clinical trial that was terminated before completion, run by Boston Scientific Corporation. The registered enrollment target is 95 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03516695 was terminated before completion, sponsored by Boston Scientific Corporation.
- TERMINATED
- Registry status
- 95 participants
- Enrollment target
Study Summary
This study is a non-interventional, observational, prospective, and global participant data registry. The study will collect effectiveness and safety data from approximately 1000 participants with liver cancers treated with TheraSphere® in a real-life setting from multiple centers globally. The absorbed dose to tumor and normal tissue will be calculated using the Simplicit90Y™ software in the subgroup of hepatocellular carcinoma (HCC) participants.
Primary Outcome
Tumor response to TheraSphere® treatment will be assessed using Modified Response Evaluation Criteria in Solid Tumors (mRECIST) or Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 depending on tumor type.
Interventions
- DEVICE TheraSphere®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2018-02-23 |
| Est. Completion | 2018-12-12 |
Why NCT03516695 stopped before completion
NCT03516695 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 95 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which TheraSphere® is the first listed.
NCT03516695 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03516695 about?
NCT03516695 is a clinical study titled "RadioEmbolization for the ADvancement of Y90 Glass Microspheres Registry". This study is a non-interventional, observational, prospective, and global participant data registry. The study will collect effectiveness and safety data from approximately 1000 participants with liver cancers treated with TheraSphere® in a real-life setting from multiple centers globally. The abso...
What is the current status of trial NCT03516695?
This trial is currently terminated. The enrollment target is 95 participants. The study started on 2018-02-23. Estimated completion is 2018-12-12.
What interventions are being tested in trial NCT03516695?
The interventions under investigation include: TheraSphere® (DEVICE).
Who is sponsoring clinical trial NCT03516695?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03339128 · 95 participants · Phase 2
Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children
- NCT03509961 · 95 participants · Phase 2
The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
- NCT03694756 · 95 participants · NA
TMEM-MRI: A Pilot Feasibility Study of MRI for Imaging of TMEM in Patients With Operable Breast Cancer
- NCT04206215 · 95 participants · NA
Noninvasive Brain Stimulation for Treating Carpal Tunnel Syndrome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI